RBC vs STVN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

RBC is the larger of the two ($14.54B market cap): the incumbent the market prices for continued execution (26.73x forward earnings, beta 1.37). STVN is the smaller challenger ($4.30B), cheaper on forward earnings (21.73x): more room to run, but more to prove. If you believe in growth, RBC fits: analysts expect its revenue to rise 11% next year, against 2% for STVN. If you believe in paying less for profit, STVN fits: it trades at 21.73x forward earnings, against 26.73x for RBC.

RBC vs STVN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricRBCSTVNWhat it tells you
Market cap$14.54B$4.30BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E26.7321.73Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E41.0926.66Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.370.80Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range17% of range31% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book4.082.40How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: STVN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how RBC and STVN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. RBC and STVN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined RBC and STVN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does RBC Bearings Incorporated (RBC) do?

RBC Bearings Incorporated, founded in 1919 and headquartered in Oxford, Connecticut, manufactures highly engineered precision bearings, gearings, and essential components for demanding applications. It reports in two segments: Aerospace and Defense (bearings and precision parts for commercial aircraft, defense aircraft, and sea and ground defense platforms) and Industrial (bearings, gearings, and components used across diversified industrial machinery). Its products are often regulated or highly technical, requiring sophisticated design, testing, and manufacturing that create high switching costs once parts are qualified into a platform.

Full RBC guide

What does Stevanato Group S.p.A. (STVN) do?

Stevanato Group has been making pharmaceutical glass in Piombino Dese, near Padua in northern Italy, since 1949, and sells its containers under the Ompi brand. The business runs in two segments. Biopharmaceutical and Diagnostic Solutions covers vials, syringes, cartridges, EZ-fill ready-to-use containers and the Alina pen injector platform, and produced ~EUR 294 million of the ~EUR 326.1 million total in the third quarter of 2026. Engineering builds the assembly, visual inspection and glass converting machinery that drug makers and other packaging firms use on their own lines, and contributed the remaining ~EUR 32 million. The company listed ordinary shares on the New York Stock Exchange in July 2021, but it remains an Italian issuer that reports in euros and files as a foreign private issuer, and the founding family retains roughly four fifths of the shares through Stevanato Holding S.r.l., with Italian loyalty-share rules adding extra votes on top of that.

Full STVN guide

RBC vs STVN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • RBC drivers: Aerospace and defense upcycle; VACCO acquisition and space exposure.
  • STVN drivers: The high-value solutions mix shift; Injectable biologics volumes, GLP-1 included.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The stock trades at a rich valuation, with a trailing P/E near ~41 and a forward P/E near ~27 as of November 2026, and roughly ~7x sales, so any growth disappointment could pressure the shares; the stock sits ~31% below its ~$668 52-week high despite consecutive beats, which shows how quickly sentiment can move. For STVN, customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month.

RBC or STVN: which should you pick?

If the story you believe is RBC's (Aerospace and defense upcycle), RBC is the more direct way to own it; if it is STVN's (The high-value solutions mix shift), STVN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the RBC and STVN guides.

RBC vs STVN: the full fundamentals

RBC. RBC Bearings has now beaten consensus in four straight quarters, and the September 2026 quarter added ~15% sales growth, a raised nine-month outlook and further debt reduction. The shares are roughly flat in 2026 (up ~0.2%) and ~7.4% higher over a year, so the multiple has compressed to about ~41x trailing and ~27x forward even as trailing earnings reached ~$11.18 a share. The mean target across 9 analysts is near ~$608, and figures are approximate as of November 20, 2026.

STVN. Every operating figure above is reported in euros because Stevanato is an Italian issuer, while the share price and market capitalization are quoted in US dollars on the NYSE, so the two sets of numbers move on different currencies and should not be compared directly. The trailing multiple has come down from ~33 times in October to ~27 times as of November 20, 2026, as the shares fell ~19% in a month on the 2027 GLP-1 warning, and consensus now looks for 2027 EPS of ~0.72 on ~EUR 1.3 billion of revenue, about ~6% growth. The analyst mean target was ~$19.46 across 12 analysts, with a Buy consensus despite the William Blair downgrade.

Headline figures (approximate, November 2026): RBC shows revenue (ttm) ~$2.02 billion, with the September 2026 quarter up ~15.2% year over year to ~$524.6 million, revenue (fy2026) ~$1.87 billion for the year ended March 2026, up about 14%, margins (ttm) Gross ~45.6%, operating ~24.7%, net ~17.5%; September 2026 quarter adjusted EBITDA margin ~33.4%, net income and eps TTM net income ~$354 million, trailing EPS ~$11.18; September 2026 quarter adjusted EPS ~$3.74 versus ~$3.53 expected; STVN shows revenue (ttm) ~EUR 1.25 billion, Q3 2026 up ~8% year over year, q3 2026 revenue ~EUR 326.1 million, adjusted diluted EPS ~EUR 0.16 (Yahoo basis 0.18 vs 0.18 est.), margins (ttm) gross ~29%, operating ~18%, net ~11%, net income (ttm) ~EUR 140 million.

The bottom line: RBC vs STVN

RBC and STVN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined RBC and STVN exposure against your real portfolio. It is not an investment adviser.

Wondering how RBC or STVN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about RBC Bearings Incorporated

Ask Walnut's AI anything about RBC and see how it fits what you own.

FAQ

What is the difference between RBC and STVN?

+

RBC Bearings Incorporated, founded in 1919 and headquartered in Oxford, Connecticut, manufactures highly engineered precision bearings, gearings, and essential components for demanding applications. Stevanato Group has been making pharmaceutical glass in Piombino Dese, near Padua in northern Italy, since 1949, and sells its containers under the Ompi brand. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is RBC or STVN the better stock?

+

Neither is universally better. RBC is the larger incumbent; STVN is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, RBC or STVN?

+

On forward P/E (as of November 2026), RBC trades at 26.73x and STVN at 21.73x, so STVN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both RBC and STVN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of RBC vs STVN?

+

RBC: The stock trades at a rich valuation, with a trailing P/E near ~41 and a forward P/E near ~27 as of November 2026, and roughly ~7x sales, so any growth disappointment could pressure the shares; the stock sits ~31% below its ~$668 52-week high despite consecutive beats, which shows how quickly sentiment can move. December-quarter guidance implies slower growth than the first half, and the quarter is seasonally exposed to delayed certification releases from defense and government customers. Naval production is behind plan on supply-chain problems, and SG&A is guided higher on stock compensation. Commercial aerospace demand is cyclical and dependent on airframer build rates that have faced supply-chain and production challenges. The Industrial segment depends heavily on GDP, which management says limits visibility. Acquisition-driven growth carries integration and leverage risk, and customer concentration in aerospace and defense programs ties results to a handful of large platforms and government budgets. STVN: Customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month. Plaintiff firms opened investigations after both episodes, the latest focused on the company's GLP-1 disclosure; those are investigations, not filed litigation, as far as the public record shows. Capital intensity remains the near-term drag, with full-year 2026 capital expenditure guided to ~EUR 230 million to ~EUR 240 million gross, trailing free cash flow of ~negative $65 million on Yahoo's basis and net debt of ~EUR 353.7 million at the end of September. GLP-1 exposure now reads as ~17% to ~18% of revenue, still a single point of failure if pricing, supply or dosing formats change, and the 2026 launch of oral GLP-1 pills turned the dosing-format risk from hypothetical to live. Governance leaves outside holders with limited influence, because family control through Stevanato Holding S.r.l. plus enhanced voting rights means minority shareholders cannot force a change of direction. Finally, the reporting currency is the euro while the quote is in dollars, so a US holder absorbs the exchange rate on top of the operating result, and at roughly ~27 times trailing and ~22 times forward earnings as of November 2026 the price still assumes the mix shift and the new plants deliver once the 2027 slowdown passes.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell RBC or STVN; figures are approximate and dated (as of November 2026). Verify current data before investing.